Internationalization, a priority for the Biotech sector in Spain

Asebio 2014 Annual Report, recently published, shows that internationalization is an essential aspect for the Spanish Biotech sector, in particular for more than 90% of the companies. In fact, 88% are developing nowadays an international activity, among them, exportation, research agreements and participation in European programmes. For the companies that haven´t still started any international activity, this issue is their priority in the short term.

Nowadays, 43 of the companies belonged to Asebio have already given the relevant step of setting up outside our borders, reaching 47 countries in the five continents. At the top of these new markets for Spanish companies are USA, Portugal and Germany, though Latin America is also in a good position. The participation in meetings and forums of the sector is a key instrument for the internationalization and the discovery of potential customers, according to the same report.

Bionaturis Group is working to offer alternative solutions for human and animal health because of its field is global. In this way, the internationalization is essential in its business model. The company is nowadays developing its expansion plan, with the setting up of BBD BioPhenix subsidiary in Maryland (USA) and the recent sign of the strategic agreement for its corporate expansion in China. Bionaturis is also working in its growth in Latin America with the firm of Carmelo Angulo.

Besides the physical presence in other countries, another of the favourite ways of the Biotech sector in its international activity is the strategic alliance, both scientific and commercial. During 2014, 97 international alliances of Spanish companies were formalized abroad. In this sense, Bionaturis Group signed last June an agreement with the company Biological Mimetics inc (BMI), located in USA, with the main goal of developing […]

August 25th, 2015|Blog english|Comments Off|

Biotechnology strengthens its position in Spain

The sales in the sector of the so-called Bioeconomy, has grown from 2.98% GDP (PIB in Spanish) in 2008 to 7.8% in 2012, according to the Asebio report, recently published. Companies stating that biotechnology is their main or only activity –among which Bionaturis is- registered an increase of 10.78% in their sales (8,800 million Euros) and 5% of rise in net employment during 2012, surpassing its own expectations for a year that it has been forecasted very complicated for Spanish economy.

According to Bionaturis’ CEO, Victor Infante, who attended the ASEBIO gala , “apart from the figures that prove that the biotech sector has performed better than others at this time of recession, I´d like to stand out some words heard today such as the need of innovation in all fields, including the relationship with public administrations, patients associations, regulatory authorities, partners at the value chain, with the main goal of seeking sustainability of the health system as a whole; or those promoting to seek talent wherever it is”.

More internationalization

85% of Asebio’s members conducted some international activity in 2013, as Bionaturis did. For the first time since this survey has been done, the associated companies consider LATAM as one of their priority market in their international strategy, specially Mexico (96.67%) and Colombia (95.83%). The European Union (93.24%), Switzerland (90.48%) and USA (88.41%) keep on having a leadership position for international operations.

During 2013, 57 companies and Spanish Organizations from the biotechnological sector (+39% regarding to 2012) signed a total of 108 international business partnerships (+42%).

August 1st, 2014|Blog english|0 Comments|

Bionaturis will attend Biospain 2014

Biospain 2014 international meeting to be hold in the beautiful city of Santiago de Compostela will gather professionals and reference companies of the Biotechnology sector. Bionaturis, specialized in developing and producing biological vaccines has already confirmed its attendance to this important forum next September.

Biospain, organized by Asebio, is hold every two years and it claimed itself as the largest biotech event organized by a national bioindustry association in Europe and one of the largest in the world by the number of one-to-one meetings (2.775) and participating companies (762). The meeting will include a trade fair, a partnering event, an investment forum, plenary sessions about business trends, and scientific lectures.  BioSpain 2014 will make the most this special year named the “Year of Biotechnology” by the Spanish government.

Bionaturis´representatives would be more than happy to meet you at Biospain 2014!

For further information about the event

You can arrange a meeting with Bionaturis´representatives by the official partnering system tool of the event or send us a request to, subjecting “BioSpain 2014 meeting”. Thank you!

You can also visit us at booth B9 during the trade fair.

2014, Year of Biotechnology in Spain

The biotech sector has one more reason to begin the new year with energy and eagerness, considering that 2014 has been quoted by the Spanish Government as the Year of Biotechnology. The Spanish Federation of Biotechnologists, along with the Spanish Society of Biotechnology (SEbiot), the Spanish Society of Microbiology (SEM), and the Spanish Association of Bio Enterprises (Asebio), have been the boosters of this initiative, which involves an important support for the industry and its professionals. In their words, the goal of this year is “not only continue encouraging the Spanish Biotech in all its sides, both research and industrial, but also improving its teaching and social concern. It’s about summing up, putting Biotech in the centre of society”.

Among the main goals of this commemoration, we have to highlight fostering Biotech research in Spain, the improvement of its teaching and dissemination, and the rise of the cooperation between the public and private sector in this field.

According to statistics from the Asebio annual report, the number of biotech companies grew more than 70% in 2011. Cataluña, Madrid and Adalucía –where Bionaturis is located- are the regions gathering more companies in this sector. The OECD ranked Spain in 2012 as the second country of the European Union with a bigger number of biotech companies.

Bionaturis congratulates the initiative and will support this commemoration, forecasting a great year for the global sector in which fostering R+D will have a key role.

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.